Stay updated on Pembrolizumab+Capecitabine in TNBC/HR+ Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab+Capecitabine in TNBC/HR+ Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab+Capecitabine in TNBC/HR+ Breast Cancer Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    8 days ago
    Change Detected
    Summary
    The clinical trial record for pembrolizumab and capecitabine is displayed, including study design, eligibility requirements, locations, outcome measures, results, and supporting documents.
    Difference
    59%
    Check dated 2026-11-08T14:35:36.000Z thumbnail image
  3. Check
    15 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov page remains a 403 Forbidden error, with its footer revision label updated from v3.7.2 to v3.8.0.
    Difference
    0.2%
    Check dated 2026-11-01T15:48:57.000Z thumbnail image
  4. Check
    22 days ago
    Change Detected
    Summary
    A site-wide NIH notice announces a transition from the term “Artificial Intelligence” to “Super Intelligence” in accordance with Executive Order 14434.
    Difference
    1%
    Check dated 2026-10-25T15:37:28.000Z thumbnail image
  5. Check
    28 days ago
    Change Detected
    Summary
    The footer revision label changes from v3.7.1 to v3.7.2 on the 403 Forbidden page.
    Difference
    0.2%
    Check dated 2026-10-18T22:21:11.000Z thumbnail image
  6. Check
    35 days ago
    Change Detected
    Summary
    The site footer revision changes from v3.7.0 to v3.7.1 while the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-11T22:12:31.000Z thumbnail image
  7. Check
    56 days ago
    Change Detected
    Summary
    The page now shows a 403 Forbidden error page, replacing the usual study record content with a basic error layout that includes a 403 header and a Home link. Access to the requested record appears restricted.
    Difference
    20%
    Check dated 2026-09-20T22:30:18.000Z thumbnail image

Stay in the know with updates to Pembrolizumab+Capecitabine in TNBC/HR+ Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab+Capecitabine in TNBC/HR+ Breast Cancer Clinical Trial page.